AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$XGN

Black Jeffrey G. sold $149K of XGN

Black Jeffrey G. (Chief Financial Officer) sold 20,614 shares of EXAGEN INC. (XGN) at $7.22 ($0.15M total) on 2026-09-01.

Original reporting
SEC EDGAR · Black Jeffrey G.
Published Sep 2, 2026, 9:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 10:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$XGN
Neutral
medium confidence
Mentioned
$XGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XGNNeutralLow
01

Why it matters

The CFO's sale is a primary disclosure but of modest size, offering limited trading insight.

02

Market read

New insider sale provides a small data point for investors monitoring insider activity.

03

What to watch

Potential upcoming corporate actions or personal liquidity needs not disclosed.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑01

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$XGNNeutralMedium confidence
Context

CFO Jeffrey G. Black sold 20,614 shares of EXAGEN for $148,781, reducing his stake to 323,339 shares.

Expected impact

Potential slight downward pressure on XGN price in the short term.

Evidence & confidence

The sale represents less than 0.05% of total shares outstanding and is unlikely to move the market significantly.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are routine.

Regional

No notable regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Company
    EXAGEN Inc.

    Biotech company listed on NASDAQ under ticker XGN.

  • Person
    Jeffrey G. Black

    Chief Financial Officer of EXAGEN.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

XGN insider trading history →

Related articles

$XGNLow

Exagen Inc. Reports Third Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% November 10, 2026 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a precisio

SEC EDGAR 8-K
$XGNMedAI 8/10

Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance

Exagen (NASDAQ:XGN) reported record Q2 2026 revenue of $19.9 million, up 16% year over year, driven by an 11% rise in AVISE CTD testing volume and a 4% higher trailing twelve-month average selling price to $446 per test. Adjusted EBITDA loss narrowed to $0.1 million. Exagen raised full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million.

yahoo.com
$XGNMedAI 8/10

Exagen Inc. Q2 2026 Earnings Call Summary

Exagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.

yahoo.com
$XGNMed

Exagen Inc. Reports Second Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million August 4,

SEC EDGAR 8-K